Search results
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Benzinga via Yahoo Finance· 5 days agoTuesday, Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for...
FDA rejects liver cancer drug combo, shares of Korean biotech tank
Endpoints News· 4 days agoKorean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the ...
Pedigree dog food recalled because it may contain metal pieces: FDA
NY Post via Yahoo News· 7 hours agoThe recalled dog food was sold in 176 stores, according to CBS News. “The potential presence of...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 27 minutes ago("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010 when we invested in the predecessor company, Isotechnika. As one of the largest and longest-standing ...
Elon Musk’s Neuralink Gets FDA Green Light to Implant Brain Chips in More Humans
The New York Observer· 9 hours agoNeuralink, the brain-computer interface startup led by Elon Musk, has achieved another milestone as...
FDA tests retail milk samples for bird flu in 17 states | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 18 hours agoThe U.S. Food and Drug Administration said today that it tested retail samples of milk and other...
FDA: Cue Health COVID tests may return false positive, negative results, so throw them away
Naples Daily News via Yahoo News· 7 days agoCheck your cabinets. The U.S. Food and Drug Administration (FDA) warned consumers and healthcare...
Critics Say FDA's Use of Surrogate Markers Falling Short
Medscape· 4 days agoAs the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are...
FDA Clears Profound Medical’s AI Model for Treating Prostate Cancer | JD Supra
JD Supra· 21 hours agoProfound Medical (Nasdaq: PROF) has received FDA 510(k) clearance for its second AI model aimed at treating prostate cancer. Profound Medical is a...
Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict
FierceBiotech· 16 hours agoThree months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis...